WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
Severe diarrhea occurred in 25% of FARYDAK treated patients. Monitor for symptoms, institute anti-diarrheal treatment...+
Offer your patients resources from the Here For You™ program
When you prescribe FARYDAK® (panobinostat) capsules, your patients and their caregivers will have access to useful tools, resources, and educational support, provided by Novartis.
A comprehensive educational brochure details how FARYDAK works, how to take it, efficacy in the clinical trial, risks, and how to help manage certain side effects.
This spiral-bound treatment journal and calendar is designed to help your patients organize important information, keep track of when to take their medications, and record topics for discussion with their health care team.
Direct your patients to www.FARYDAK.com for additional information.
FARYDAK® (panobinostat) capsules, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
IMPORTANT SAFETY INFORMATION